• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.

作者信息

Wu M, Sun J, Zhang Y, Huang F, Zhou H, Fan Z, Xuan L, Yu G, Guo X, Dai M, Feng R, Liu Q

机构信息

Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

出版信息

Bone Marrow Transplant. 2016 Mar;51(3):456-8. doi: 10.1038/bmt.2015.281. Epub 2015 Nov 23.

DOI:10.1038/bmt.2015.281
PMID:26595071
Abstract
摘要

相似文献

1
Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.鞘内注射利妥昔单抗治疗对基于静脉注射利妥昔单抗的治疗无反应的伴有中枢神经系统受累的EB病毒相关移植后淋巴细胞增生性疾病：一项前瞻性研究。
Bone Marrow Transplant. 2016 Mar;51(3):456-8. doi: 10.1038/bmt.2015.281. Epub 2015 Nov 23.
2
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.造血干细胞移植后局限于中枢神经系统的 EBV 相关移植后淋巴组织增生性疾病患者鞘内注射利妥昔单抗后获得持续缓解。
Pediatr Blood Cancer. 2012 Mar;58(3):459-61. doi: 10.1002/pbc.23134. Epub 2011 May 16.
3
Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.鞘内注射利妥昔单抗治疗移植后淋巴组织增生性疾病中枢神经系统累及。
Leuk Lymphoma. 2013 Mar;54(3):503-6. doi: 10.3109/10428194.2012.718342. Epub 2012 Aug 31.
4
Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.儿童和成人造血干细胞移植后 EBV 相关淋巴组织增生性疾病对利妥昔单抗治疗的反应及危险因素分析：来自欧洲血液和骨髓移植学会传染病工作组的研究。
Clin Infect Dis. 2013 Sep;57(6):794-802. doi: 10.1093/cid/cit391. Epub 2013 Jun 13.
5
Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.异基因造血干细胞移植后 Epstein-Barr 病毒相关白血病淋巴瘤
J Clin Virol. 2016 Jul;80:82-6. doi: 10.1016/j.jcv.2016.04.020. Epub 2016 May 6.
6
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.单剂量与多剂量利妥昔单抗用于造血细胞移植后 EBV 再激活的抢先治疗。
Leuk Lymphoma. 2019 Jan;60(1):110-117. doi: 10.1080/10428194.2018.1459603. Epub 2018 Jul 6.
7
Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.同种异体干细胞移植中 EB 病毒的再激活与巨细胞病毒的再激活高度相关。
Clin Transplant. 2013 Jul-Aug;27(4):E491-7. doi: 10.1111/ctr.12172. Epub 2013 Jun 19.
8
Successful Treatment of Central Nervous System Involvement in Posttransplant EBV-related Lymphoproliferative Disease With Intrathecal Rituximab Therapy.鞘内利妥昔单抗治疗移植后 EBV 相关淋巴增殖性疾病所致中枢神经系统受累的疗效
J Pediatr Hematol Oncol. 2023 Jul 1;45(5):e628-e630. doi: 10.1097/MPH.0000000000002592. Epub 2022 Nov 15.
9
Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.引入聚合酶链反应监测病毒载量后异基因造血干细胞移植中的移植后淋巴细胞增殖性疾病及其他EB病毒疾病
Scand J Infect Dis. 2007;39(3):235-44. doi: 10.1080/00365540600978906.
10
Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.造血干细胞移植后监测爱泼斯坦-巴尔病毒载量以早期干预移植后淋巴细胞增生性疾病。
J Med Virol. 2008 Mar;80(3):441-54. doi: 10.1002/jmv.21096.

引用本文的文献

1
Intrathecal rituximab in pediatric CD20-positive central nervous system limited lymphoproliferative disease: report of two cases and literature review.鞘内注射利妥昔单抗治疗儿童CD20阳性中枢神经系统局限性淋巴增殖性疾病：两例报告及文献综述
Ann Hematol. 2025 May 5. doi: 10.1007/s00277-025-06386-y.
2
[Clinical significance of Epstein-Barr Virus detection in the cerebrospinal fluid of patients who underwent hematopoietic stem cell transplantation].[造血干细胞移植患者脑脊液中爱泼斯坦-巴尔病毒检测的临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2023 Sep 14;44(9):737-741. doi: 10.3760/cma.j.issn.0253-2727.2023.09.006.
3
[Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation (2022)].

本文引用的文献

1
EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.体内T细胞去除的同种异体移植后EB病毒相关移植后淋巴细胞增殖性疾病：利妥昔单抗时代的临床特征、病毒载量相关性及预后因素
Bone Marrow Transplant. 2014 Feb;49(2):280-6. doi: 10.1038/bmt.2013.170. Epub 2013 Nov 11.
2
Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植受者中与 EBV 相关疾病的谱。
Transplantation. 2013 Sep;96(6):560-6. doi: 10.1097/TP.0b013e31829d38af.
3
[造血干细胞移植后EB病毒相关移植后淋巴增殖性疾病诊断和管理的中国专家共识（2022年）]
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):716-725. doi: 10.3760/cma.j.issn.0253-2727.2022.09.002.
4
Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.成人移植后淋巴细胞增生性疾病的最新进展
Cancers (Basel). 2022 Dec 1;14(23):5949. doi: 10.3390/cancers14235949.
5
A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.急性淋巴细胞白血病患者行单倍体造血干细胞移植后中枢神经系统移植后淋巴组织增生性疾病 1 例
Cell Transplant. 2022 Jan-Dec;31:9636897221117532. doi: 10.1177/09636897221117532.
6
Epstein-Barr Virus Encephalitis and Disseminated Adenovirus Infection after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for a Patient with Ph-Like Acute Lymphoblastic Leukemia.一位患有Ph样急性淋巴细胞白血病的患者在单倍体异基因造血干细胞移植后发生的爱泼斯坦-巴尔病毒脑炎和播散性腺病毒感染
Case Rep Oncol. 2022 Mar 14;15(1):245-250. doi: 10.1159/000522556. eCollection 2022 Jan-Apr.
7
Successful treatment of central nervous system lymphoproliferative disorder in a kidney-pancreas and stem cell transplanted patient using intrathecal rituximab.利妥昔单抗鞘内注射成功治疗肾胰联合干细胞移植后中枢神经系统淋巴增殖性疾病
BMJ Case Rep. 2021 Aug 5;14(8):e238236. doi: 10.1136/bcr-2020-238236.
8
Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后爱泼斯坦-巴尔病毒相关移植后淋巴增殖性疾病的管理
Ther Adv Hematol. 2020 Apr 28;11:2040620720910964. doi: 10.1177/2040620720910964. eCollection 2020.
9
Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.异基因造血干细胞移植后中枢神经系统移植后淋巴细胞增生性疾病：长崎移植组的经验
Leuk Res Rep. 2019 Apr 22;11:27-30. doi: 10.1016/j.lrr.2019.04.003. eCollection 2019.
10
Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.移植后淋巴组织增生性疾病后非弥漫性大 B 细胞淋巴瘤的治疗。
Curr Treat Options Oncol. 2018 May 24;19(7):33. doi: 10.1007/s11864-018-0549-6.
Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
鞘内注射利妥昔单抗治疗移植后淋巴组织增生性疾病中枢神经系统累及。
Leuk Lymphoma. 2013 Mar;54(3):503-6. doi: 10.3109/10428194.2012.718342. Epub 2012 Aug 31.
4
Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.移植后淋巴组织增生性疾病：风险、分类和治疗建议。
Curr Treat Options Oncol. 2012 Mar;13(1):122-36. doi: 10.1007/s11864-011-0177-x.
5
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.造血干细胞移植后局限于中枢神经系统的 EBV 相关移植后淋巴组织增生性疾病患者鞘内注射利妥昔单抗后获得持续缓解。
Pediatr Blood Cancer. 2012 Mar;58(3):459-61. doi: 10.1002/pbc.23134. Epub 2011 May 16.
6
Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.高危患者异基因造血干细胞移植后预防 EBV 再激活和移植后淋巴增殖性疾病（PTLD）的策略。
Biol Blood Marrow Transplant. 2011 May;17(5):591-7. doi: 10.1016/j.bbmt.2010.08.007. Epub 2010 Aug 21.
7
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.80 例实体器官移植后发生移植后淋巴组织增生性疾病患者的多中心分析：现代时代的结局和预后因素。
J Clin Oncol. 2010 Feb 20;28(6):1038-46. doi: 10.1200/JCO.2009.25.4961. Epub 2010 Jan 19.
8
Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.原发性中枢神经系统移植后淋巴组织增生性疾病：国际原发性中枢神经系统淋巴瘤协作组报告。
Cancer. 2010 Feb 15;116(4):863-70. doi: 10.1002/cncr.24834.
9
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后淋巴增殖性疾病的危险因素。
Blood. 2009 May 14;113(20):4992-5001. doi: 10.1182/blood-2008-09-178046. Epub 2009 Mar 5.
10
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.利妥昔单抗脑室内给药治疗复发性中枢神经系统和眼内淋巴瘤的I期研究。
J Clin Oncol. 2007 Apr 10;25(11):1350-6. doi: 10.1200/JCO.2006.09.7311. Epub 2007 Feb 20.